154 related articles for article (PubMed ID: 14751359)
21. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
22. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
[TBL] [Abstract][Full Text] [Related]
23. Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate.
Oefelein MG; Grayhack JT; McVary KT
Cancer; 1995 Dec; 76(12):2535-42. PubMed ID: 8625082
[TBL] [Abstract][Full Text] [Related]
24. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
25. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
[TBL] [Abstract][Full Text] [Related]
26. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
27. Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less.
D'Amico AV; Chen MH; Malkowicz SB; Whittington R; Renshaw AA; Tomaszewski JE; Samofalov Y; Wein A; Richie JP
J Urol; 2002 May; 167(5):2025-30; discussion 2030-1. PubMed ID: 11956431
[TBL] [Abstract][Full Text] [Related]
28. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy.
Kupelian PA; Elshaikh M; Reddy CA; Zippe C; Klein EA
J Clin Oncol; 2002 Aug; 20(16):3376-85. PubMed ID: 12177097
[TBL] [Abstract][Full Text] [Related]
30. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
31. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution.
Martinez AA; Gonzalez JA; Chung AK; Kestin LL; Balasubramaniam M; Diokno AC; Ziaja EL; Brabbins DS; Vicini FA
Cancer; 2000 Jan; 88(2):425-32. PubMed ID: 10640977
[TBL] [Abstract][Full Text] [Related]
32. Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer.
Gore JL; Penson DF; Litwin MS
Nat Clin Pract Urol; 2006 Aug; 3(8):449-52. PubMed ID: 16902521
[TBL] [Abstract][Full Text] [Related]
33. Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.
Hoffman RM; Lo M; Clark JA; Albertsen PC; Barry MJ; Goodman M; Penson DF; Stanford JL; Stroup AM; Hamilton AS
J Clin Oncol; 2017 Jul; 35(20):2306-2314. PubMed ID: 28493812
[TBL] [Abstract][Full Text] [Related]
34. The results of radical prostatectomy at a community hospital during the prostate specific antigen era.
Smitt MC; Heltzel M
Cancer; 1996 Mar; 77(5):928-33. PubMed ID: 8608486
[TBL] [Abstract][Full Text] [Related]
35. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density.
Allan RW; Sanderson H; Epstein JI
J Urol; 2003 Aug; 170(2 Pt 1):370-2. PubMed ID: 12853777
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
37. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
[TBL] [Abstract][Full Text] [Related]
38. Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy.
Tsien C; Griffith KA; Sandler HM; McLaughlin P; Sanda MG; Montie J; Reddy S; Hayman JA
Urology; 2003 Jul; 62(1):93-8. PubMed ID: 12837430
[TBL] [Abstract][Full Text] [Related]
39. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate.
Gonzalgo ML; Bastian PJ; Mangold LA; Trock BJ; Epstein JI; Walsh PC; Partin AW
Urology; 2006 Jan; 67(1):115-9. PubMed ID: 16413345
[TBL] [Abstract][Full Text] [Related]
40. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
